U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
- “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
- After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.